The development of COVID-19 treatment
Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
Therapeutic advances in COVID-19
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …
millions of lives. Unlike the early days of the pandemic, when management decisions were …
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …
in patients with viral respiratory diseases, and are currently being investigated in trials as …
Vaccines and therapeutics for immunocompromised patients with COVID-19
The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …
This diverse group is at increased risk for impaired vaccine responses, progression to …
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
CM Denkinger, M Janssen, U Schäkel, J Gall, A Leo… - Nature Cancer, 2023 - nature.com
Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …
high morbidity and mortality. Furthermore, impaired humoral response renders severe acute …
Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
The latest SARS-CoV-2 variant of concern Omicron, with its immune escape from
therapeutic anti-Spike monoclonal antibodies and WA-1 vaccine-elicited sera, demonstrates …
therapeutic anti-Spike monoclonal antibodies and WA-1 vaccine-elicited sera, demonstrates …
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents
N Perico, M Cortinovis, F Suter… - The Lancet Infectious …, 2023 - thelancet.com
Summary COVID-19, caused by SARS-CoV-2, is characterised by a broad spectrum of
symptom severity that requires varying amounts of care according to the different stages of …
symptom severity that requires varying amounts of care according to the different stages of …
Clinical practice guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 convalescent plasma
Description: Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a
potential treatment of COVID-19. However, meta-analysis data and recommendations are …
potential treatment of COVID-19. However, meta-analysis data and recommendations are …
Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study
Background Cytokines and chemokines play a critical role in the response to infection and
vaccination. We aimed to assess the longitudinal association of COVID-19 vaccination with …
vaccination. We aimed to assess the longitudinal association of COVID-19 vaccination with …
Antibody and B cell responses to SARS-CoV-2 infection and vaccination: the end of the beginning
As the COVID-19 pandemic has evolved during the past years, interactions between human
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …